Streetbeat News

Regulatory

DBVT

DBV Technologies shares rose following regulatory updates for their Viaskin Peanut patch in the US and Europe.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:10 pm

UPXI

Upexi, Inc. (NASDAQ:UPXI) has regained compliance with Nasdaq's minimum bid price rule after maintaining a closing bid price of $1.00 or greater from October 3 to October 16, 2024. The company plans to file its delayed Form 10-K by November 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:09 pm

BWB

Bridgewater Bancshares, Inc. (NASDAQ:BWB) has received all necessary regulatory approvals to acquire First Minnetonka City Bank. The acquisition is expected to close in Q4 2024, pending customary closing conditions.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:08 pm

ALUR

Allurion Technologies has submitted the first three modules of its Premarket Approval (PMA) application to the FDA for the Allurion Balloon, a weight loss device. This marks a significant step in the regulatory process for the company.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:02 pm

GE

GE Aerospace is collaborating with Lilium to develop safety standards for electric vertical takeoff and landing (eVTOL) aircraft. This partnership aims to enhance flight safety in the emerging eVTOL industry.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:33 am

TSLA

Palo Alto is considering a deal with Tesla to test robotaxis on its streets, but the decision depends on California regulators. Tesla plans to start autonomous driving with Model 3 and Model Y in Texas and California next year, with the Cybercab joining by 2026.

Portfolio Pulse from Anan Ashraf

October 23, 2024 | 11:28 am

MCD

McDonald's shares are experiencing a decline due to a CDC report linking an E. coli outbreak to their quarter pounders.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:15 am

RNAZ

TransCode Therapeutics has received approval from its Safety Review Committee to open the second cohort of patients in its Phase 1 clinical trial, following a positive safety review of the first cohort.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:10 am

AGIO

Agios Pharmaceuticals has completed enrollment for its Phase 3 RISE UP study of Mitapivat, a treatment for sickle cell disease. This milestone is significant for the company's development pipeline and potential future revenue streams.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 11:09 am

GOOGL

META

The Hong Kong government has banned the use of WhatsApp and Google Drive on civil servants' work computers due to security concerns. This move is part of a global trend of governments imposing restrictions on digital platforms for security reasons.

Portfolio Pulse from Benzinga Neuro

October 23, 2024 | 10:01 am